With immense pleasure, it is a great honor to welcome all the Oncologists, Radiologists, Cancer Researchers, Academicians, Pathologists, Specialized doctors, Young scientists, Business Delegates and Hospital Associates, Social Management Associates to the ‘21st Global Experts meeting on Oncology Case Reports’ that will be held in London, UK going to be held during August 29-31, 2017 .
Oncology Meet 2017 will be organized by Allied Academies. It is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies. This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).
Why to attend Oncology Meet 2017?
Oncology Case Reports are the evidences/study done towards the treatment of cancer. It is a case series evidence based study which plays a crucial role in the field of medical research.
Oncology Meet 2017 will cover the entire spectrum of oncology, including prevention, diagnosis, treatment, toxicities of therapy, supportive care, quality-of-life, and survivorship issues in the field of cancer & oncology. It will include the use of novel technologies, both in the arena of diagnosis and treatment in the fight against this dreadful disease. This conference will provide clinicians and researchers with a platform to disseminate their personal experiences to a wider public as well as to know interesting cases encountered by colleagues all over the world.
Oncology Meet 2017 will showcase the recent discoveries/advances performed towards the treatment of cancer. The conference will provide with an exceptional opportunity for the delegates from Universities and Institutes to interact with the world class Scientists and Industry Professionals working in the field of cancer/oncology. It is a perfect platform to share knowledge from biomedical researches to the implementation of those researches to acquire the seamless treatment procedures.
The conference will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and discuss new research in the field of cancer & oncology, including discussions on oncology.
- Microbiologists & Epidemiologists
- Delegates from Clinical Research Centers
- Young Researchers working with Hospitals
Market Analysis Report
Oncology Meet 2017 with a basic emphasis in the field of cancer/oncology are research studies done which are performed to explore new medical treatments to implement them in people. These play a major role exploration & furtherance of therapies for medical care. People that usually are related with the clinical trial in the field on cancer & oncology are comprises of registered Oncologists, Surgical Oncologists, Scientists, Physicians, Nurses & Clinical specialists working for cancer treatment etc..
Oncology Case Report 2017 will cover the entire spectrum of oncology, including prevention, diagnosis, treatment, toxicities of therapy, supportive care, quality-of-life, and survivor-ship issues in the field of cancer & oncology. It will include the use of novel technologies, both in the arena of diagnosis and treatment in the fight against this dreadful disease. This conference will provide clinicians and researchers with a platform to disseminate their personal experiences to a wider public as well as to know interesting cases encountered by colleagues all over the world.
London is the capital and most populous city of England
and the United Kingdom with resident population of 7,375, making it the
smallest city in England. Standing on the River Thames, London has been a major
settlement for two millennia. It’s a city where old and new amiably clash, high
culture rubs shoulders with pearly queens – with its streets paved with regal
London is a leading global city, with strengths of
heritage, arts, commerce, education, entertainment, fashion, finance, research
and development, healthcare, media, professional services and tourism. In UK
more than 80 Universities/ colleges, 145 pharmaceutical companies, and more
than 60 Associations and societies are working on Hemophilia and other blood
related disorders. Funding grants by the government of china for research
nearly 200 million USD$ to universities and 1.5 billion USD$ to the pharmaceutical
and research institutes.
· Association of Cancer Physicians
· BASO The Association for Cancer Surgery
· British Gynaecological Cancer Society
· Cancer Focus Northern Ireland
· Cancer Research UK
· Childhood Cancer Research Group
· Children with Cancer UK
· Children’s Cancer and Leukaemia Group
· Prostate Cancer UK
· UK Oncology Nursing Society
· United Kingdom Association of Cancer Registries
Irish Cancer Society
Cancer Research UK
Peter McCollum Cancer Centre
Cancer Society of New Zealand
American Society of Clinical Oncology (ASCO)
International Agency for Research on Cancer (IARC)
American Association for Cancer Research (AACR)
International Cancer Research Partnership (ICRP)
National Cancer Institute (NIC)
The European Cancer Organization (ECCO)
Medical Centre Cologne
German Cancer Research Centre
associated on Oncology:
Leiden University Medical Center
Royal Cancer Hospital
King’s College Hospital
Clatterbridge Center for Oncology
Northampton General Hospital
Cambridge University Hospitals
University Hospital Southhampton
Central Manchester University Hospitals
Southend University Hospital
Institute of Oncology, Ljubljana
Institut Gustave Roussy, Paris
Paterson Institute On Cancer Research, UK
Imperial College Hospital
The Royal Marsden Hospital in London, England
New York Presbyterian Hospital
Memorial Sloan Kettering Cancer Center
Mayo Clinic Rochester
MD Anderson Cancer Center, Texas
John Hopkins Hospital, Baltimore
University of Washington Medical Center
Massachusetts General Hospital
UCSF Medical Center
UCLA Medical Center
City of Hope,CA
University of Colorado Hospital
Institute of Cancer Research.London
Dana-Farber Cancer Institute in Boston, USA
Memorial Sloan Kettering (MSK) Cancer Center, New York City
Hospitals of the University of Pennsylvania–Penn Presbyterian,
Seidman Cancer Center at UH Case Medical, Cleveland
University of Colorado Hospital, Denver
Hackensack University Medical Center – Hackensack, New Jersey
Georgetown University Medical Center (Washington, D.C.).
Montefiore Medical Center (New York City)
The Toledo (Ohio) Hospital.
University of Iowa Hospitals and Clinics (Iowa City).
University of Virginia Medical Center (Charlottesville)
Yale-New Haven (Conn.) Hospital.
The pace of change in cancer care is accelerating. A
cluster of innovative treatments, often combined with other new or existing
medicines, and frequently associated with biomarkers, are emerging from the
research and development pipeline.
Over the past five years, 70 new oncology treatments
have been launched and are being used to treat over 20 different tumour types.
Annual global growth in the oncology drug market is
expected to be 7.5 – 10.5 % through 2020, reaching $150 billion. Wider
utilization of new products—especially immunotherapies—will drive much of the
growth, offset by reduced use of some existing treatments with inferior
Oncology drug costs relative to total drug costs range from
2.5% in the case of India to almost 16% in the case of Germany and France. In
the U.S., cancer drugs account for 11.5% of total drug costs in 2015, up from
10.5% in 2011.
The total cost of cancer therapeutics and medicines used
in supportive care– measured at the ex-manufacturer price level before the
application of rebates or other price concessions – reached $107 billion in
2015, representing an increase in constant dollars of 11.5% over the prior